January 31, 2017
Ipsen buys gastrointestinal-focused-portfolio Italian company
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
January 31, 2017
European Commission OK’s Novartis’s tuberous sclerosis complex drug
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
January 30, 2017
Novo Nordisk invests £115 in new type 2 diabetes research with Oxford
Novo Nordisk and University of Oxford have expanded their partnership on researching type 2 diabetes, and will open a new research centre in Oxford.
January 30, 2017
Short: Shield’s secretary officially resigns
Shield Therapeutics has appointed Capita Registrars Limited as company secretary, after Richard Jones has officially resigned.
January 30, 2017
CHMP recommends Pfizer’s rheumatoid arthritis drug for European approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…
January 30, 2017
InnovaDerma appoints acquisition specialist as a Non-Executive Director
InnovaDerma has appointed Kieran Callan as a Non-Executive Director with immediate effect, succeeding Garry Lemair who stepped down from the…
January 30, 2017
Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
January 30, 2017
Realm Therapeutics asks FDA’s approval for its first IND for atopic dermatitis treatment
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).
January 30, 2017
Sanofi welcomes Kathleen Tregoning to its Executive Committee
Sanofi has appointed Kathleen Tregoning, Biogen’s senior Vice President of Corporate Affairs, as a new member of the Executive Committee, effective February 27, 2017.